Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 58,064 | 109,899 | 178,311 | 223,235 | 378,021 |
| Marketable Securities | 222,767 | 217,278 | 217,761 | 210,823 | 127,255 |
| Receivables | 21,996 | 4,682 | 1,090 | 8,247 | 10,673 |
| Other current assets | 31,310 | 16,661 | 20,019 | 0 | 5,422 |
| TOTAL | $338,488 | $355,652 | $426,038 | $467,233 | $532,823 |
| Non-Current Assets | |||||
| PPE Net | 12,644 | 12,189 | 12,662 | 12,899 | 13,176 |
| Investments And Advances | 4,985 | 24,939 | 0 | 0 | 11,869 |
| Other Non-Current Assets | 52,709 | 52,557 | 53,747 | 51,133 | 2,367 |
| TOTAL | $70,338 | $89,685 | $66,409 | $64,032 | $27,412 |
| Total Assets | $408,826 | $445,337 | $492,447 | $531,265 | $560,235 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 9,851 | 8,701 | 12,348 | 8,300 | N/A |
| Accounts payable and accrued liabilities | 4,758 | 8,713 | 3,501 | 5,596 | 9,028 |
| Accrued Expenses | 38,233 | 33,369 | 29,253 | 32,337 | 26,889 |
| TOTAL | $111,703 | $108,823 | $110,136 | $113,542 | $98,554 |
| Non-Current Liabilities | |||||
| Long Term Debt | 219,300 | 222,008 | 217,715 | 221,402 | 229,535 |
| Deferred Revenues | 31,575 | 33,751 | 43,311 | 42,515 | 43,402 |
| Other Non-Current Liabilities | 294,902 | 283,142 | 288,376 | 287,840 | 249,580 |
| TOTAL | $520,963 | $519,319 | $519,535 | $530,975 | $513,270 |
| Total Liabilities | $632,666 | $628,142 | $629,671 | $644,517 | $611,824 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 62,520 | 56,762 | 56,637 | 56,137 | 55,580 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | -1,248,600 | -1,182,994 | -1,124,563 | -1,084,725 | -1,012,145 |
| Other shareholders' equity | 145 | 94 | 129 | -36 | -166 |
| TOTAL | $-223,840 | $-182,805 | $-137,224 | $-113,252 | $-51,589 |
| Total Liabilities And Equity | $408,826 | $445,337 | $492,447 | $531,265 | $560,235 |